KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) FCF Margin: 2011-2024

Historic FCF Margin for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -7.21%.

  • Esperion Therapeutics' FCF Margin rose 6380.00% to -4.91% in Q3 2025 from the same period last year, while for Sep 2025 it was -30.71%, marking a year-over-year decrease of 2188.00%. This contributed to the annual value of -7.21% for FY2024, which is 10925.00% up from last year.
  • Per Esperion Therapeutics' latest filing, its FCF Margin stood at -7.21% for FY2024, which was up 93.81% from -116.46% recorded in FY2023.
  • Esperion Therapeutics' 5-year FCF Margin high stood at -7.21% for FY2024, and its period low was -336.29% during FY2021.
  • Over the past 3 years, Esperion Therapeutics' median FCF Margin value was -116.46% (recorded in 2023), while the average stood at -118.44%.
  • Per our database at Business Quant, Esperion Therapeutics' FCF Margin tumbled by 29,847bps in 2021 and then spiked by 11,517bps in 2023.
  • Esperion Therapeutics' FCF Margin (Yearly) stood at -37.81% in 2020, then crashed by 29,847bps to -336.29% in 2021, then spiked by 10,465bps to -231.64% in 2022, then spiked by 11,517bps to -116.46% in 2023, then surged by 10,925bps to -7.21% in 2024.